Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML
Sponsor: National Cancer Institute (NCI)
Listed as NCT00425477, this PHASE2 trial focuses on Leukemia and Myelodysplastic Syndromes and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 11 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Oct 2018 [monthly]
Unknown Status PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States